Pharmathen, a company with a history of 53 years and a pioneer in Research & Development of innovative technologies and pharmaceutical products, was awarded for its business excellence in “Research and Innovation” at the Growth Awards 2022. The award ceremony took place on Tuesday, November 1st at the Peristyle of Zappeion Megaron, organized by Grant Thornton and Eurobank.
Pharmathen, one of the top pharmaceutical companies in Europe and a leader in complex Long Acting Injectables (LAI), has proven once again that innovation is in the DNA of its 1.250 people. Pharmathen remains the largest private investment organization in the Research and Development sector in Greece and one of the largest in Europe, with an R&D investment plan of €300 million by 2026. This plan includes a new innovation hub in Attica, which will be completed in 2025. The company already has two state-of- the-art production units in Pallini, Attica and in Sapes, Rodopi and its portfolio consists of 30 new products and is expected to expand even more.
The award was received on behalf of Pharmathen by George Drossos, Vice President People & Culture, who stated:
“We are proud of this distinction tonight, at the Growth Awards, among leading companies, for our business excellence in “Research and Innovation”.
This award comes as a recognition for all the people of Pharmathen, for their passion, innovation and commitment to make the difference in people’s lives through their everyday work.”
With regards to this distinction, Dimitris Kadis, CEO of Pharmathen, noted:
“At Pharmathen, innovation is part of our DNA. By continuously investing in new technologies, pharmaceutical products and, more importantly, our people, we are improving people’s lives every day around the world and enhancing our country’s extroversion.”